Evidence map›Paper›PMID 28868257›Full record

ReviewEuropean thyroid journal2017

Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Mohammad-Reza Mahmoudian-Sani, Ameneh Mehri-Ghahfarrokhi, Majid Asadi-Samani, Gholam-Reza Mobini

Abstract readReview
In one paragraph

Review in European thyroid journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. The role of exosomal long non-coding RNAs in head, neck and thyroid cancers.Medical oncology (Northwood, London, England) · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammad-Reza Mahmoudian-SaniResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Ameneh Mehri-GhahfarrokhiCellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Majid Asadi-SamaniStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Gholam-Reza MobiniCellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThyroid cancer is the most common endocrine malignancy and accounts for 1% of cancers. In recent years, there has been much interest in the feasibility of using miRNAs or miRNA panels as biomarkers for the diagnosis of thyroid cancer. miRNAs are noncoding RNAs with 21-23 nucleotides that are highly conserved during evolution. They have been proposed as regulators of gene expression, apoptosis, cancer, and cell growth and differentiation.

methodsThe Directory of Open Access Journals (DOAJ), Google Scholar, PubMed (NLM), LISTA (EBSCO), and Web of Science were searched.

resultsThe serum level of miRNAs (miRNA-375, 34a, 145b, 221, 222, 155, Let-7, 181b) can be used as molecular markers for the diagnosis and prognosis of thyroid cancer in the serum samples of patients with thyroid glands.

conclusionsGiven that most common methods for the screening of thyroid cancer cannot detect the disease in its early stages, identifying miRNAs that are released in the bloodstream during the gradual progression of the disease is considered a key method in the early diagnosis of thyroid cancers.

Indexed as

BiomarkerFine-needle aspiration biopsymiRNAThyroid cancer

Identifiers

PMID28868257
PMCPMC5567107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.